rapcabtagene autoleucel Oncology: Hematology Phase 2 ≥ 2027 CD19 CART (CD19-targeted chimeric antigen receptor T-cell immunotherapy) 1L high-risk large B-cell lymphoma Lead Indication PrintPDF